Celcuity (NASDAQ:CELC) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Celcuity (NASDAQ:CELC) had its price objective increased by equities researchers at Stifel Nicolaus from $68.00 to $115.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 24.08% from the company’s previous close.

A number of other research firms have also issued reports on CELC. HC Wainwright boosted their price objective on Celcuity from $66.00 to $77.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Guggenheim assumed coverage on Celcuity in a research report on Monday, September 22nd. They set a “buy” rating on the stock. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a report on Monday, October 20th. Leerink Partners raised their price objective on shares of Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, July 28th. Finally, Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $91.00.

Celcuity Trading Up 7.8%

Shares of Celcuity stock opened at $92.68 on Thursday. The stock’s 50-day simple moving average is $61.61 and its 200 day simple moving average is $36.77. Celcuity has a 52-week low of $7.57 and a 52-week high of $94.06. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The stock has a market capitalization of $3.93 billion, a P/E ratio of -25.25 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.13. The business had revenue of $0.15 million during the quarter. As a group, research analysts anticipate that Celcuity will post -2.62 EPS for the current year.

Institutional Trading of Celcuity

Hedge funds have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV purchased a new position in Celcuity in the third quarter worth $27,000. US Bancorp DE boosted its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Celcuity by 611.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock valued at $79,000 after purchasing an additional 1,369 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Celcuity during the 3rd quarter valued at about $79,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.